CAS Patents

Our patent collection is augmented with English titles and abstracts and detailed indexing by CAS scientists, making complex aspects of patent documents, including chemical substances, sequences, Markush structures, assignees, and classification codes, searchable and accessible.

Contact us
Hexagon shaped overlay
Glowing blue technical blueprint of a circular mechanical part with measurements and circuit-like background.

Features

Patents published by 109 issuing authorities covering more than 40,000 unique IPC codes in areas including chemistry, pharmaceuticals, consumer goods, processes, materials, engineering, agriculture, and more.

English language titles and abstracts for patents published in 50 languages translated and enhanced by CAS scientists.

Key invention details including substances, reactions, Markush representations, and more indexed by scientists and connected to other relevant data within the CAS Content Collection™.

Consolidated patent family summaries and convenient connections to global full-text patent documents.

Claims text, legal status information, cited references, and examiner citations included for select authorities.

Updated daily, with patent applications from nine major patent issuing authorities available within two days of publication.

Latest from CAS Insights™

Emerging Science

Are perovskite solar panels the future of green energy?

Perovskite solar panels are cheaper and more efficient than other PVs, yet advances in materials and fabrication are needed to make them commercially viable. Our in-depth analysis reveals the research hot spots and new opportunities.
|Article
Emerging Science

Nipah virus explained: Risks, realities, and the hope from new research

New Nipah cases in India have renewed focus on a high‑fatality zoonotic threat shaped by complex spillover dynamics, severe neurological disease, and limited medical countermeasures. Meanwhile, global efforts in diagonistcs, therapeutics, and vaccines are accelerating.
|Article
Biotechnology

Innovations in cancer immunotherapy: Bi-specific T cell engagers

Bi-specific T cell engagers are poised to become key immunotherapy treatments due to simpler production and new safety advances.
|Article